Narnatumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD22 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
Chemical and physical data | |
Formula | C6454H10026N1754O2020S44 |
Molar mass | 145.9 kg/mol |
|
Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.[2]
Narnatumab was developed by ImClone Systems.
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab" (PDF). American Medical Association.
- ↑ "Narnatumumab". AdisInsight. Retrieved 31 January 2017.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.